Grifols, SA (ES:GRF)
BME:GRF
GRF Stock Chart & Stats
€9.20
-€0.12(-1.30%)
At close: 4:00 PM EST
€9.20
-€0.12(-1.30%)
Day’s Range― - ―
52-Week Range€7.32 - €13.70
Previous CloseN/A
Volume312.38K
Average Volume (3M)1.09M
Market Cap
€5.71B
Enterprise Value€15.08B
Total Cash (Recent Filing)€825.49M
Total Debt (Recent Filing)€9.64B
Price to Earnings (P/E)18.7
Beta0.87
Next Earnings
Apr 30, 2026EPS Estimate
0.14Next Dividend Ex-DateN/A
Dividend Yield1.37%
Share Statistics
EPS (TTM)0.14
Shares Outstanding426,129,800
10 Day Avg. Volume1,216,950
30 Day Avg. Volume1,090,725
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)1.40
Price to Sales (P/S)0.98
P/FCF Ratio9.41
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€11.00Price Target Upside19.57% Upside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)0.87
Revenue Forecast (FY)€7.78B
Bulls Say, Bears Say
Bulls Say
Vertical Integration / Plasma Supply ModelControl of the plasma value chain (donation centers through fractionation and distribution) creates durable supply reliability and margin capture. Owning collection and manufacturing reduces supplier risk, supports consistent product availability, and sustains recurring revenue from therapies and diagnostics.
Revenue Growth And Improving MarginsMid-to-high single-digit revenue growth and a meaningful margin rebound reflect recovering demand and better operating leverage. Sustained top-line growth with improved profitability increases cash generation potential and supports reinvestment or gradual balance-sheet repair over the medium term.
Positive Free Cash Flow GenerationConsistent positive operating and free cash flow provides the firm durable internal funding for capex, working capital and deleveraging. Solid FCF coverage of earnings (~0.75x) improves financial flexibility versus the 2022–2023 trough and supports ongoing business investment or debt reduction.
Bears Say
High LeverageA large absolute debt load and elevated debt-to-equity materially constrain strategic flexibility. High leverage increases refinancing and interest-rate vulnerability, limits capacity for M&A or larger R&D investments, and raises the probability that earnings shocks translate into balance-sheet stress.
Cash Coverage Of Debt Is LimitedAlthough FCF is positive, operating cash remains small relative to total debt and recent FCF growth deceleration signals that deleveraging will be gradual. Low coverage lengthens the horizon to materially reduce leverage and keeps liquidity and refinancing risk elevated over the medium term.
Margin Shortfall And Earnings VolatilityWhile margins have recovered, they are still materially under historical peaks and earnings volatility persists. This reduces predictability of cash flows and returns, complicates long-term planning and investment decisions, and weakens confidence in sustained margin expansion absent structural margin drivers.
Grifols News
GRF FAQ
What was Grifols, SA’s price range in the past 12 months?
Grifols, SA lowest stock price was €7.32 and its highest was €13.70 in the past 12 months.
What is Grifols, SA’s market cap?
Grifols, SA’s market cap is €5.71B.
When is Grifols, SA’s upcoming earnings report date?
Grifols, SA’s upcoming earnings report date is Apr 30, 2026 which is in 23 days.
How were Grifols, SA’s earnings last quarter?
Grifols, SA released its earnings results on Feb 26, 2026. The company reported €0.144 earnings per share for the quarter, missing the consensus estimate of €0.255 by -€0.111.
Is Grifols, SA overvalued?
According to Wall Street analysts Grifols, SA’s price is currently Undervalued.
Does Grifols, SA pay dividends?
Grifols, SA pays a Annually dividend of €0.15 which represents an annual dividend yield of 1.37%. See more information on Grifols, SA dividends here
What is Grifols, SA’s EPS estimate?
Grifols, SA’s EPS estimate is 0.14.
How many shares outstanding does Grifols, SA have?
Grifols, SA has 426,129,800 shares outstanding.
What happened to Grifols, SA’s price movement after its last earnings report?
Grifols, SA reported an EPS of €0.144 in its last earnings report, missing expectations of €0.255. Following the earnings report the stock price went up 1.004%.
Which hedge fund is a major shareholder of Grifols, SA?
Currently, no hedge funds are holding shares in ES:GRF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Grifols Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€11.00 (19.57% Upside)
€11.00 (19.57% Upside)
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
21.39%
12-Months-Change
Fundamentals
Return on Equity
7.56%
Trailing 12-Months
Asset Growth
-7.75%
Trailing 12-Months
Company Description
Grifols, SA
Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalent, and life-threatening diseases. It offers immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins. The Hospital division offers non-biological pharmaceutical products and medical supplies clinical nutrition, intravenous therapy, and medical devices. The Diagnostic division researches, develops, produces, and commercializes diagnostic products that span the healthcare continuum from prevention, screening, diagnosis, and prognosis to disease and treatment monitoring to serve professionals. The Bio Supplies division provides biological materials for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.
GRF Stock 12 Month Forecast
Average Price Target
€11.00
▲(19.57% Upside)
Technical Analysis
Almirall
―
Faes Farma
―
LABORATORIO REIG JOFRE
―
Laboratorios Farmaceuticos Rovi
―
Pharma Mar SA
―
Options Prices
Currently, No data available
---